<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385565</url>
  </required_header>
  <id_info>
    <org_study_id>2004/0401</org_study_id>
    <secondary_id>2004/0138</secondary_id>
    <nct_id>NCT02385565</nct_id>
  </id_info>
  <brief_title>Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy</brief_title>
  <acronym>MITOX</acronym>
  <official_title>Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare Resting Energy Expenditure (REE) between normal&#xD;
      fat diet (NFD) as a control vs high fat diet (HFD) as a treatment in Mitochondrial&#xD;
      cytopathies disorders ( MID's ) patients. Secondary objectives is to compare diet induced&#xD;
      thermogenesis (DIT) and body composition between NFD vs HFD.&#xD;
&#xD;
      This study is a randomized cross-over study. Normal fat diet (ie 10 % proteins, 45 % lipids,&#xD;
      45 % carbohydrates) is the imposed diet at baseline, high fat diet (ie 10 % proteins, 30 %&#xD;
      lipids, 60 % carbohydrates is used according to the cross-over design trial. Main evaluation&#xD;
      criteria is REE and second evaluation criteria is DIT both measured by indirect calorimetry&#xD;
      ). 36 included MID subjects will be included in this study. Main evaluation criteria and&#xD;
      second evaluation criteria will be measured at baseline, 1 month, 2 month and 3 month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REE and DIT are measured by indirect calorimetry . The device used is a using an open-circuit&#xD;
      ventilated hood system (QUARK RMR®, Cosmed, Pavona; Italy). The respiration quo- tient (RQ)&#xD;
      and flow settings are calibrated by reference to alcohol combustion every six months. Before&#xD;
      each test, the calorimeter is calibrated with a reference gas mixture (5% CO2, 95% O2 v/v).&#xD;
      Expired carbon di- oxide (VCO2) and inspired oxygen (VO2) -flows are recorded, as well as the&#xD;
      RQ. EE is calculated every minute from oxygen consumption (VO2 in ml/min) and carbon dioxide&#xD;
      production (VCO2 in ml/min) using the Weir formula without protein correction. DIT is&#xD;
      measured during 6 hours after a calibrated breakfast (normal fat diet or high fat diet&#xD;
      according to the cross-over design) as 30% of theoric energy intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>resting energy expenditure</measure>
    <time_frame>up to 3 months</time_frame>
    <description>resting energy expenditure measured by indirect calorimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diet induced thermogenesis</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months</time_frame>
    <description>diet induced thermogenesis measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>baseline, 1 month, 2 months, 3 months</time_frame>
    <description>body composition by DEXA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Mitochondrial Cytopathies Disorders</condition>
  <arm_group>
    <arm_group_label>high fat diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 % proteins, 30 % lipids, 60 % carbohydrates</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal fat diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 % proteins, 45 % lipids, 45 % carbohydrates</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high fat diet</intervention_name>
    <description>high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates</description>
    <arm_group_label>high fat diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal fat diet</intervention_name>
    <description>high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates</description>
    <arm_group_label>Normal fat diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5 to 21 years-old children,&#xD;
&#xD;
               -  Children with a proven mitochondrial cytopathy documented on biopsies by&#xD;
                  histology, histoenzymology, ultrastructure and enzyme assay and/or on body fluids&#xD;
                  by laboratory markers including lactacidemia, metabolic acidosis, increased CSF&#xD;
                  lactate, lactate/pyruvate and beta-hydroxybutyrate/acetoacetate ratios,&#xD;
                  paradoxical postprandial ketonemia, alaninemia, citrullinemia, plasma&#xD;
                  acylcarnitines.&#xD;
&#xD;
               -  Children on the usual diet (30% lipids, 60% glucides and 10% proteins) for at&#xD;
                  least 1 month.&#xD;
&#xD;
               -  Informed consent of the 2 parents and from the child when in age to express a&#xD;
                  consent.&#xD;
&#xD;
               -  Child with a social security cover.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute infection (fever &gt; 38.5°C for more than 6h) within 7 days prior to the study.&#xD;
&#xD;
          -  Disability for understanding and following the protocol&#xD;
&#xD;
          -  Rejection of the study by the patient or failure to comply to the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dries DOBBELAERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kearns-Sayre Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

